Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Drug discovery, Neurological, Neuroscience

Rejuvenating Alzheimer’s R&D

Developing drugs for chronic diseases of aging is notoriously difficult. But addressing the health burden associated with such conditions is becoming increasingly urgent as the world’s population ages (1). The Alzheimer’s Drug Discovery Foundation (ADDF) highlights the need to focus on neurodegenerative disorders and to date has invested more than US$150 million to fund over 626 Alzheimer’s drug discovery programs and clinical trials in 19 countries (2).

“Biotechs and academics are still pursuing novel targets and innovation in new drugs,” Howard Fillit, the ADDF’s Founding Executive Director and Chief Science Officer. “With support from investors and venture philanthropies and government, risk can be taken.  As these succeed, the ‘external’ R&D model will proceed to create opportunities for licensing and acquisition of new drugs in development.”

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

About the Author

Maryam Mahdi

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register